Abbott Laboratories (ABT) reported Q1 adjusted earnings Wednesday of $1.09 per diluted share, up from $0.98 a year earlier.

Analysts polled by FactSet expected $1.07.

Revenue for the quarter ended March 31 was $10.36 billion compared with $9.96 billion a year earlier.

Analysts surveyed by FactSet expected $10.41 billion.

For Q2, the company said it expects adjusted diluted earnings per share of $1.23 to $1.27. Analysts surveyed by FactSet expect $1.25.

Abbott reaffirmed its 2025 adjusted diluted earnings per share guidance of $5.05 to $5.25. Analysts surveyed by FactSet expect $5.15. The company also reiterated its annual organic sales growth to be 7.5% to 8.5%. Analysts polled by FactSet expect $44.40 billion.